Preview

Онкоурология

Расширенный поиск

ВНУТРИПУЗЫРНАЯ ТЕРАПИЯ РАКА МОЧЕВОГО ПУЗЫРЯ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ

https://doi.org/10.17650/1726-9776-2011-7-3-136-133

Полный текст:

Аннотация

Внутрипузырная химио-/иммунотерапия является составной частью комплексного лечения рака мочевого пузыря и широко применяется после трансуретральной резекции опухоли. Цель интравезикальной терапии состоит в снижении риска развития рецидива и прогрессии заболевания за счет прямого цитотоксического воздействия на злокачественное новообразование. Уникальные свойства мочевого пузыря позволяют постоянно совершенствовать существующие и создавать новые методы местного лечения, такие как внутрипузырный электрофорез, локальная гипертермия, генная терапия, применение веществ-пенетрантов и магнитных частиц. Представленный обзор объединяет физико-химические свойства и фармакокинетическую характеристику лекарств, особенности гистоархитектоники мочевого пузыря, настоящее и будущее внутрипузырной терапии.

Об авторах

В. В. Протощак
Кафедра урологии ГОУ ВПО ВМА им. С.М. Кирова
Россия


А. В. Кукушкин
Кафедра урологии ГОУ ВПО ВМА им. С.М. Кирова
Россия


П. А. Бабкин
Кафедра урологии ГОУ ВПО ВМА им. С.М. Кирова
Россия


А. Ю. Шестаев
Кафедра урологии ГОУ ВПО ВМА им. С.М. Кирова
Россия


Н. Д. Кубин
Кафедра урологии и андрологии Санкт-Петербургской медицинской академии последипломного образования, Санкт-Петербург
Россия


Е. С. Шпиленя
Кафедра урологии и андрологии Санкт-Петербургской медицинской академии последипломного образования, Санкт-Петербург
Россия


А. И. Новиков
Кафедра урологии и андрологии Санкт-Петербургской медицинской академии последипломного образования, Санкт-Петербург
Россия


Список литературы

1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2009.

2. Rene N.J., Cury F.B., Souhami L. Conservative treatment of invasive bladder cancer. Curr Oncol 2009;16(4): 36–47.

3. American Cancer Society. Cancer facts and figures. American Cancer Society, Atlanta, GA, 2007.

4. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2):74−108.

5. Simons M.P., O’Donnell M.A., Griffith T.S. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol; 2008 Jul-Aug; 26(4):341–5.

6. Матвеев Б.П. и др. Клbladder cancer, intravesical therapy, immunotherapy, chemotherapyиническая онкоурология. М., 2003. 7. Schenk-Braat E.A., Bangma C.H. Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother. 2005; 54(5):414−23.

7. Jalón Monzón A., Fernández Gómez J.M., Escaf Bramada S. et al.Therapeutic effect of immediate postoperative mitomycin C in patients with low-risk non-muscle-invasive bladder tumors. Actas Urol Esp 2008;32(8):811−20.

8. Hicks R.M., Ketterer В., Warren R.C. Isolation and characterization of the urothelial lumenal plasma membrane J Cell Biol 1977;73(2): 382–99.

9. De Bruijn E.A., Sleeboom H.P., van Helsdingen P.J. et al. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int J Cancer 1992;51(3):359−64.

10. Chai M., Wientjes M.G., Badalament R.A. et al. Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol 1994; 152(2 Pt 1):374−8.

11. Song D., Wientjes M.G., Au J.L. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 1997;40(4):285−92.

12. Kirkali Z., Chan T., Manoharan M. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66 (6 Suppl 1):4−34. 14. Underberg W. J., Lingeman H. Aspects of the chemical stability of mitomycin and porfiromycin in acidic solution. J. Pharm Sci 1983; 72(5):549−53.

13. See W.A., Xia Q. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 1992;84(7):510−5.

14. Ilett K.F., Ong R.T., Batty K.T., Taylor J.D. Effect of urine pH on the stability of doxorubicin and its recovery from bladder instillations. Br J Urol 1990; 65(5):478−82.

15. Harris N.M., Duffy P.M., Crook T.J. et al. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. BJU Int 2002; 90(9):957−64.

16. Grabnar I., Bogataj M., Belic A. et al. Kinetic model of drug distribution in the urinary bladder wall following intravesical instillation. Int J Pharmac 2006; 322(1−2):52−9.

17. Shen Z., Shen T., Wientjes M.G. et al. Intravesical treatments of bladder cancer: review. Pharm Res 2008; 25(7):1500−10.

18. Mellett J.B., Woods L.A. The comparative physiological disposition of thiotepa and tepa in the dog. Cancer Res1960;20:524–32.

19. Morales A., Eidinger D., Bruce A.W. Intracavitary Ba cillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116(2):180−3.

20. Alexandroff A.B., Jackson A.M., O’Donnell M.A., James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet; 1999;353(9165):1689−94.

21. Sylvester R.J., van der Meijden A.P., Lamm D.L. In travesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168(5):1964−70.

22. Han R.F., Pan J.G. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67(6):1216−23.

23. Witjes J.A., Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analy sis of currently available drugs, treatment schedules, and longterm results. Eur Urol 2008;53(1):45−52.

24. Smaldone M.C., Gingrich J.R. Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer. Minerva Urol Nefrol 2010; 62(2):129−32.

25. Babjuk M., Oosterlinck W., Sylvester R. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the blad der. Eur Urol 2008; 54(2):303−14.

26. Malkowicz S.B. The role of intravesical chemotherapy in the treatment of bladder cancer. In: S. P. Lerner, M. Schoenberg, C. Sternberg (eds.). Textbook of Bladder Cancer, Informa Healthcare, London, 2006; p. 335–340.

27. Nilsson S., Ragnhammar P., Glimelius B., Nygren P.; SBU-group. Swedish Council of Technology As sessment in Health Care. A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol 2001;40(2−3):371−90.

28. Bartoletti R., Cai T., Gacci M. et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology 2005;66(4):726−31.

29. Dalbagni G., Russo P., Bochner B. et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24(18):2729−34.

30. Серегин И.В., Самойленко В.М., Фигурин К.М. Внутрипузырное применение гемцитабина у больных поверхностным раком мочевого пузыря, резистентным к внутрипузырной иммунотерапии вакциной БЦЖ. Онкоурология 2005;(2):32−3.

31. Grossman B.H., O’Donnell M.A., Cookson M.S. et al. Bacillus Calmette-Guerin Failures and Beyond: contemporary management of non-muscle-invasive bladder. Cancer Rev Urol 2008;10(4):281−9.

32. Steinberg G., Bahnson R., Brosman S. et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163(3):761−7.

33. Sylvester R.J., van der Meijden A.P., Witjes J.A., Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174(1):86−91.

34. Böhle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1):90−5.

35. Shelley M.D., Wilt T.J., Court J. et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93(4):485−90.

36. Böhle A., Bock P.R. Intravesical bacilli Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal metaanalysis of comparative studies on tumor progression. Urology 2004; 63(4):682−6.

37. Sylvester R.J. Natural history, recurrence, and progres sion in superficial bladder cancer. Scientific World Journal 2006; 6:2617−25.

38. Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemo therapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171(6 Pt 1):2186−90.

39. Hall M.C., Chang S.S., Dalbagni G. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178(6):2314−30.

40. Chen D., Song D., Wientjes M.G., Au J.L. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res 2003; 9(1):363−9.

41. Grabnar I., Bogataj M., Mrhar A. Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall. Int J Pharm 2003; 256(1−2):167−73.

42. Hobarth K., Maier U., Marberger M. Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. Eur Urol 1992; 21(3):206−10.

43. Lokeshwar V.B., Estrella V., Lopez L. et al. HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res 2006;66(23):11219−27.

44. Visage C.Le, Rioux-Leclercq N., Haller M. et al. Efficacy of paclitaxel released from bioadhesive polymer microspheres on model superficial bladder cancer. J Urol 2004;171(3):1324−9.

45. Ye Z., Chen J., Zhang X. et al. Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer. J Tongji Med Univ 2001; 21(2):145−8.

46. Leakakos T., Ji C., Lawson G. et al. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Canc Chem Pharmacol 2003; 51(6):445−50.

47. Moskovitz B., Beyer M.G., Kravtzov A. et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005;16(4):585−9.

48. Красный С.А., Суконко О.Г., Поляков и С.Л. др. Внутрипузырная электрохимиотерапия в лечении поверхностного рака мочевого пузыря. UroWeb.ru. http://www.uroweb.ru/db/article/942.html

49. Di Stasi S.M., Giannantoni A., Massoud R. et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration- depth profiles studies. Cancer Res 1999; 59(19):4912−8.

50. Di Stasi S.M., Verri C., Capelli G. et al. Single immediate preoperative instillation of Electromotive Mitomycin-C for Primary Non-Muscle Invasive Bladder Cancer: A Randomized Prospective Trial. EUA Annual Congress — Barcelona 2010 [Abstr 196]. EAU Barcelona 2010 webcasts. http://www.eaubarcelona2010.org/?id=176&S=26273

51. Di Stasi S.M., Massoud S., Dolci S. et al. Concentration-dept profiles of Mitomycin-C in the human bladder wall after passive diffusion, termo-chemotherapy and electromotive drug administration. EUA Annual Congress — Barcelona 2010 [Abstr 196]. EAU Barcelona 2010 webcasts. http://www.eaubarcelona2010.org/?id=176&S=26274

52. Di Stasi S.M., Giannantoni A., Giurioli A. et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomized controlled trial. Lancet Oncol 2006; 7:43–51.

53. Fodor I., Timiryasova T., Denes B. et al. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 2005; 173(2):604−9.

54. Connor R.J., Anderson J.M., Machemer T. et al. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 2005; 66(1):224−9.

55. Horiguchi Y., Larchian W.A., Kaplinsky R. et al. Intravesical liposomemediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther 2000;7(10):844−51.


Для цитирования:


Протощак В.В., Кукушкин А.В., Бабкин П.А., Шестаев А.Ю., Кубин Н.Д., Шпиленя Е.С., Новиков А.И. ВНУТРИПУЗЫРНАЯ ТЕРАПИЯ РАКА МОЧЕВОГО ПУЗЫРЯ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ. Онкоурология. 2011;7(3):136-133. https://doi.org/10.17650/1726-9776-2011-7-3-136-133

For citation:


Protoshchak V.V., Kukushkin A.V., Babkin P.A., Shestayev A.Y., Kubin N.D., Shpilenya E.S., Novikov A.I. INTRAVESICAL THERAPY FOR BLADDER CANCER: STATE-OF-THE ART. Cancer Urology. 2011;7(3):136-133. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-3-136-133

Просмотров: 617


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)